Balancing Leadership Turmoil and Focused Clinical Strategy: Maintaining a Buy on Cardiff Oncology’s Onvansertib Amid Catalyst-Rich Outlook

William Blair analyst Andy Hsieh has maintained their bullish stance on CRDF stock, giving a Buy rating today.

Andy Hsieh has given his Buy rating due to a combination of factors that balance near-term uncertainty with longer-term opportunity for Cardiff Oncology’s lead asset, onvansertib. Despite the abrupt departures of the CEO and CFO and the interim leadership arrangement, he appears to believe that the core clinical program in RAS‑mutated colorectal cancer retains meaningful value. The strategic shift to concentrate development on the onvansertib plus FOLFIRI and bevacizumab regimen narrows the initial market scope, yet it also reflects a more focused path that could streamline regulatory and clinical execution.

At the same time, the updated Phase II data in combination with FOLFIRI and Avastin show a numerically strong progression‑free survival signal, with a hazard ratio consistent with a substantial potential reduction in the risk of progression or death, even though the wide confidence interval and small sample size warrant caution. Hsieh appears to view the upcoming detailed data disclosure, longer follow‑up, and clarification of the regulatory strategy—likely to be shared around a major oncology conference—as important catalysts that could further validate the program. Although the company will probably need additional capital or a partnership to finance a pivotal trial, its current cash position provides a runway to reach these value‑defining events, supporting his decision to maintain a Buy rating while modestly lowering the probability of success.

Hsieh covers the Healthcare sector, focusing on stocks such as Terns Pharmaceuticals, Exelixis, and Nektar Therapeutics. According to TipRanks, Hsieh has an average return of 12.7% and a 47.25% success rate on recommended stocks.